Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000921895-25-001982
Filing Date
2025-07-09
Accepted
2025-07-09 19:55:34
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 22857
  Complete submission text file 0000921895-25-001982.txt   24686
Mailing Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104
Business Address 44 MONTGOMERY STREET 40TH FL SAN FRANCISCO CA 94104 3125066500
BIOTECHNOLOGY VALUE FUND L P (Filed by) CIK: 0000918923 (see all company filings)

EIN.: 363924731 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Subject) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89140 | Film No.: 251114604
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)